arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Vaxcyte, Inc.

PCVX
$56.50 ▼ -2.56 (-4.33%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
32 Visible periods
21 Metrics
Peer-ranked Benchmarks
Price Chart
34
Health
Poor
Bearish
auto_awesome

Analytical Summary

Vaxcyte, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $8.2B
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -8.7% ↗
FCF / Share $-1.64 ↗
Trailing P/E —
Price / Book 3.0x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

32-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-320.62M
↓ -127.8% —
FCF / Share Free cash flow per share
$-1.64
↓ -81.3% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↑
24
Cash Quality ↓
59

Dividend History

Dividend / share · sourced from SEC filings
$0.00 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 9 years · 32 quarters